Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi, Merck Pediatric Combo Vaccine Available in U.S.

06/01/2021 | 05:53am EDT

By Matt Grossman

Sanofi and Merck & Co.'s pediatric combination vaccine for six diseases is now available in the U.S., the companies said Tuesday.

The vaccine protects against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and invasive disease due to Haemophilus influenzae type b. The vaccine, called Vaxelis, has been approved as a three-dose series in children between 6 weeks old and four years old.

Use of the vaccine reduces the number of shots children would get in their first six months of life, said Joanne Monahan, senior vice president of U.S. vaccines at Merck.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

06-01-21 0753ET

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.51% 35105.59 Delayed Quote.14.55%
MERCK & CO., INC. -1.79% 76.925 Delayed Quote.-4.24%
SANOFI -1.22% 86.52 Real-time Quote.11.30%
All news about SANOFI
12:25pSANOFI : Online availability of Sanofi's half-year financial report for 2021
GL
10:01aGLOBAL MARKETS LIVE : Earnings reports please investors
10:00aSANOFI : Sales growth accelerated - Full-year guidance raised (Form 6-K)
PU
07:46aSANOFI : Gets a Buy rating from JP Morgan
MD
07:38aSANOFI : Buy rating from Goldman Sachs
MD
05:10aSANOFI : Q2 Earnings Snapshot
AQ
05:00aREGENERON, SANOFI : Dupixent Hits Endpoints in Chronic Spontaneous Urticaria
DJ
04:22aSANOFI : Posts Higher Q2 Earnings, Net Sales; Raises 2021 Non-GAAP EPS Outlook
MT
04:02aSANOFI : Regeneron's Hives Drug Reduces Itch In Late-Stage Study
MT
02:44aSanofi raises profit forecast after second quarter beat
RE
More news
Financials
Sales 2021 36 920 M 43 887 M 43 887 M
Net income 2021 5 946 M 7 068 M 7 068 M
Net Debt 2021 6 704 M 7 970 M 7 970 M
P/E ratio 2021 17,8x
Yield 2021 3,74%
Capitalization 108 B 129 B 129 B
EV / Sales 2021 3,12x
EV / Sales 2022 2,87x
Nbr of Employees 99 412
Free-Float 88,3%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 87,59 €
Average target price 102,63 €
Spread / Average Target 17,2%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI11.30%129 607
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750